Datavault AI Expands DataMEDS Licensing Agreement Into Commercial Healthcare

Datavault AI (NASDAQ: DVLT) announced on July 30, 2026, that it has expanded its definitive licensing agreement with DataMeds AI Inc. to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.

Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.

This expansion is significant as it moves Datavault AI’s technology from a niche pharmaceutical focus to a broader healthcare ecosystem, potentially revolutionizing how patients control and monetize their own health data. The integration of blockchain and AI-driven remote patient monitoring could address key challenges in healthcare data interoperability and patient privacy. According to the press release, the global health and wellness market is rapidly expanding, and this agreement positions Datavault AI to capture a share of that growth by providing secure, patient-centric data solutions.

The company’s Data Science division leverages Web 3.0 and high-performance computing to enable secure monetization of data, while its Acoustic Sciences division includes patented technologies for spatial audio. The expanded agreement suggests that Datavault AI’s platform, which already serves industries like sports, entertainment, and biotech, is now targeting healthcare more directly. The behavioral healthcare patent portfolio underpinning the agreement includes technologies for medical logistics and IoT population health, which could improve efficiency in healthcare delivery and patient outcomes.

Datavault AI’s platform enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. This capability could be particularly valuable in healthcare for creating digital representations of patient health data that are secure and verifiable. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.

The full press release is available at https://ibn.fm/vBAxH. For more information about Datavault AI, visit https://dvlt.ai. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.